Relationship between the gene polymorphism of osteoprotegerin, serum osteoprotegerin level and chronic kidney disease in south Indian populations
European Journal of Molecular & Clinical Medicine,
2022, Volume 9, Issue 2, Pages 1818-1824
AbstractIntroduction: CKD-MBD is thus thought to be a major contributor to the high mortality among patients with CKD. The negative regulation of osteoclastic bone resorption exerted by OPG could increase BMD and bone volume by decreasing the active osteoclasts as demonstrated by in vitro studies
Methodology: This is an observational study with no interventions carried out on any subject. Furthermore, all the CKD individuals were made two groups based on the dialysis. Finally, the analyses was done between the predialysis, dialysis and control population to find the possible or potential diagnostic marker for CKD-MBD.
Results: Distribution of rs3102735genotypes between the non-dialysis and dialysis groups were not found significant differences for allelic (OR: 1.54, 95% CI (0.65-3.60)), genetic TT vs TC (OR: 1. 81, 95% CI (0.48-6.76) p=0.37) TT vs CC (OR: 1. 70, 95% CI (0.36-7.85) p=0.49) and dominant (OR: 1.77, 95% CI (0.57-5.50) p=0.32) models. Similarly, we have not found significant difference for rs3102735 in recessive model (OR: 0.72, 95% CI (0.16-3.09) p=0.662).
Conclusion: The serum OPG may be a useful biomarker for early diagnosis of CKD-MBD.
- Article View: 27
- PDF Download: 75